Results 141 to 150 of about 30,070 (260)

Clinical Features and Therapeutic Outcomes in Pyoderma Gangrenosum: A Prospective Cohort Study

JEADV Clinical Practice, Volume 5, Issue 2, Page 495-501, June 2026.
ABSTRACT Background Pyoderma gangrenosum (PG) is a rare neutrophilic dermatosis highly associated with systemic comorbidities. Accurate diagnosis and treatment remain challenging due to its rarity and clinical mimickers. Objectives To evaluate demographic, clinical features and treatment outcomes in patients referred with suspected PG at a tertiary ...
David Croitoru, Nesrine Brahimi, Haleh Zabihi, Cathryn Sibbald, Kyle Seigel, Delaram Shojaei, Eric McMullen, Afsaneh Alavi, Lily Archaempong, Aaron M. Drucker, Adam Weizman, Kenneth Croitoru, Robert Inman, Vincent Piguet   +13 more
wiley   +1 more source

Parameter estimation in a Myeloproliferative neoplasm model

, 2017
The aim of thisprojectwork was toestimate the parameter values in a given modelwhichcontainsfourcouplednon-linearordinarydifferentialequations, and access if the given model of the leukemia Myeloproliferative neoplasm disease is a good representative of ...
Temizsoy, Mehmet, Nørr, Maria Nicoline, Rasmussen, Jeannie Bøg   +2 more
core  

The Dual Role of Autophagy in Cancer: Mechanisms and Therapeutic Strategies

MedComm – Oncology, Volume 5, Issue 2, June 2026.
Autophagy is a conserved cellular process degrading dysfunctional organelles and protein aggregates to maintain cell homeostasis, and it exhibits context‐dependent duality in cancer. Autophagy functions as a critical tumor‐suppressive mechanism by preventing DNA damage and mutation during tumor initiation.
Xiang‐Zheng Gao, Yuheng Qin, Haoyu Wan, Guang Lu, Han‐Ming Shen   +4 more
wiley   +1 more source

Outcomes for ruxolitinib only versus combination with interferon in treating patients with myelofibrosis

Blood Neoplasia
Katie Erdos, Aya Alshareef, Richard T. Silver, Joseph M. Scandura, Ghaith Abu-Zeinah   +4 more
doaj   +1 more source

On‐Scanner Correction of Gradient Nonlinearity Bias for Accurate Assessment of Diffusion Heterogeneity Across Bone Sites in Myelofibrosis Patients

Magnetic Resonance in Medicine, Volume 95, Issue 6, Page 3386-3395, June 2026.
ABSTRACT Purpose To improve accuracy of apparent diffusion coefficient (ADC) measurement across different bone‐marrow (BM) sites for myelofibrosis (MF) patients. Methods Vendor‐provided ADC gradient nonlinearity correction (GNC) was implemented for 41 MF study subjects on a 3T clinical scanner.
Dariya Malyarenko, Brian D. Ross, Johannes M. Peeters, Ajit Devaraj, Ramin Jafari, Humera Tariq, Kristen M. Pettit, Moshe Talpaz, Gary D. Luker, Thomas L. Chenevert   +9 more
wiley   +1 more source

The microenvironment in myeloproliferative neoplasm

HemaSphere, 2018
Simón Méndez-Ferrer, Claudia Korn
doaj   +1 more source

Myeloproliferative neoplasms

HemaSphere, 2019
openaire   +3 more sources

Pre‐RAI Monocyte‐to‐Lymphocyte Ratio Predicts Early and Higher Recurrence Risk in Intermediate‐Risk DTC, While PNI and NRI Show No Prognostic Value

Clinical Endocrinology, Volume 104, Issue 6, Page 670-681, June 2026.
ABSTRACT Objective Differentiated thyroid carcinoma (DTC) has an excellent prognosis, but recurrence remains a clinical concern, especially in intermediate‐risk patients. Current stratification systems focus primarily on tumor characteristics, overlooking the host's biological capacity to counteract tumor progression.
Tommaso Piticchio, Francesco Galeano, Salvatore Volpe, Antonio Prinzi, Ignazio Barca, Andrea Scuto, Rosario Le Moli, Giulio Geraci, Andrea Tumminia, Sium Wolde Sellasie, Francesco Pallotti, Francesco Frasca   +11 more
wiley   +1 more source

Tumor‐Specific Success Probabilities and Factors Associated With Phase III Trials in Oncology Drug Development

Clinical and Translational Science, Volume 19, Issue 6, June 2026.
ABSTRACT Despite advances in novel therapeutic modalities, such as molecularly targeted agents and immunotherapies, the probability of success in Phase III oncology trials remains low. This study quantitatively characterized success probabilities of Phase III trials in oncology drug development and evaluated the factors associated with trial success ...
Keiko Yamamoto, Aya Iwase, Hideki Maeda
wiley   +1 more source

Improvement of psoriasis with ruxolitinib in a patient with myeloproliferative neoplasm: a therapeutic observation. [PDF]

An Bras Dermatol
Gomide LV, Ribeiro AMQ.
europepmc   +1 more source